| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10963128 | Vaccine | 2015 | 8 Pages |
Abstract
H4:IC31 demonstrated an acceptable safety profile and was immunogenic in South African adults. In this trial, the 15 μg dose appeared to induce the most optimal immune response.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Hennie Geldenhuys, Helen Mearns, David J.C. Miles, Michele Tameris, David Hokey, Zhongkai Shi, Sean Bennett, Peter Andersen, Ingrid Kromann, Søren T. Hoff, Willem A. Hanekom, Hassan Mahomed, Mark Hatherill, Thomas J. Scriba,